Naspro 250 Tablet: Each tablet contains 250 mg Naproxen BP.
Naspro 500 Tablet: Each tablet contains 500 mg Naproxen BP.
Naspro is a preparation of Naproxen, a non-steroidal anti-inflammatory agent. The drug exhibits anti-inflammatory, analgesic, and antipyretic activity. Naproxen is an inhibitor of prostaglandin synthesis. Naproxen is readily and completely absorbed from G.I. tract and presence of food may delay its rate of absorption. Peak plasma concentration is attained 2 to 4 hours after ingestion. At therapeutic concentration Naproxen is more than 99% bound to plasma proteins and has a plasma half-life of about 13 hours. About 30% of a dose of Naproxen is metabolized in the liver. Approximately 95% of the drug is excreted in urine.
Naproxen is indicated for the treatment of rheumatoid arthritis, osteoarthritis (degenerative arthritis), ankylosing spondylitis, juvenile rheumatoid arthritis, acute gout, and acute musculoskeletal disorders (such as sprains and strains, direct trauma, lumbosacral pain, cervical spondylitis, tenosynovitis and fibrositis) and dysmenorrhea.
Adult: Rheumatoid arthritis, osteoarthritis and ankylosing spondylitis: the usual dose is 500 mg to 1 g daily taken at 12-hour intervals or alternatively as a single administration of two tablets morning or evening.
Acute gout: 750 mg initially, then 250 mg every eight hours until the attack has passed.
Acute musculoskeletal disorders: 500 mg initially followed by 250 mg at 6-8 hour intervals as needed to a maximum 1250 mg daily.
Children: Naproxen is effective in the treatment of juvenile rheumatoid arthritis in children over five years of age at a dose of 10 mg/kg day taken in two doses at 12-hour intervals.
*Prescription only*
The natriuretic effects of frusemide have been reported to be inhibited by some drugs of this class.
Naproxen and other non-steroidal anti-inflammatory drugs can reduce the anti-hypertensive effect of propranolol and other beta-blockers. Probenecid given concurrently increases Naproxen plasma levels and extends its half-life considerably. Concurrent administration of methotrexate may enhance its toxicity due to reduced tubular secretion.
Naproxen should be given under close supervision to patients with a history of gastrointestinal disease. Bronchospasm may be precipitated in patients suffering from, or with history of bronchial asthma or allergic disease. As Naproxen is eliminated to a large extent (95%) by urinary excretion via glomerular filtration, it should be used with great caution in patients with impaired renal function and the monitoring of serum creatinine clearance is advised in these patients. Naproxen is not recommended in patients having baseline creatinine clearance less than 20 ml/minute.
Use in pregnancy and lactation: Naproxen affects the human fetal cardiovascular system (closure of the ductus arteriosus), and use of this class of therapeutic agent requires cautious balancing of possible benefit against potential risk to the mother and fetus especially in the first and third trimesters. Naproxen has been found in the milk of lactating mothers. The use of Naproxen should therefore be avoided in patients who are breast-feeding.
Overdosage:
Significant overdosage of the drug may be characterized by drowsiness, heartburn, indigestion, and nausea or vomiting. It is not known what dose of the drug would be life threatening.
Store at below 30°C in a dry place protected from light. Keep out of reach of children.